Mylan surges, Teva slumps after FDA approves Copaxone copy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval
October 4, 2017 7:27 AM EDTBTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy rating after the company received final FDA approval for its generic versions of Tevas (NASDAQ: TEVA) 20mg and 40mg... More
